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The 1st International Standard (IS) for blood coagulation factor XI (FXI), plasma, has 
been successfully used for potency labeling of FXI therapeutics and for diagnosis of FXI 
deficiency in patients. With stocks of the 1st IS near depletion, a replacement is required. 
In addition to the functional activity value, assignment of an antigen value to the 2nd IS 
would allow harmonization of antigen assay methods and differentiation of patients who 
have low functional activity but normal antigen FXI levels from patients who have both 
low functional and antigen FXI levels. The aims of this study were, therefore, to assign 
FXI functional activity to the 2nd IS for FXI, plasma, and to additionally assign a new 
analyte, FXI antigen, to the same International Standard. The candidate material was 
prepared from double-spun, virology negative, normal plasma, which was pooled and 
filled into siliconized glass ampoules and subsequently freeze-dried. Assignment of the 
functional activity (FXI:C) value in International Units (IUs) was performed by one-stage 
clotting assay by 29 laboratories, relative to the 1st IS. The overall geometric mean (GM) 
was 0.71 IU/amp with extremely low inter-laboratory variability (expressed as geomet-
ric coefficient of variation) of 1.8%. The antigen value assignment was performed by 
11 laboratories and was calculated relative to normal plasma pools, as is customary 
with new coagulation factor analytes. The amount of antigen present in 1 ml of normal 
plasma was taken to be 1 U. The overall GM for the antigen assays was 0.78 IU/amp 
with an inter-laboratory variation of 10%. The candidate (National Institute for Biological 
Standards and Control code, 15/180) was established by the World Health Organization 
(WHO) Expert Committee on Biological Standardization in 2016 as the WHO 2nd IS for 
blood coagulation FXI, plasma, with a functional activity value (FXI:C) of 0.71 IU/amp and 
an antigen value (FXI:Ag) of 0.78 IU/amp.
Keywords: international standard for factor Xi, factor Xi functional activity, factor Xi antigen, measurement of 
factor Xi, multicentre study
inTrODUcTiOn
Bleeding disorders associated with factor XI (FXI) deficiency are generally mild and bleeding is 
most often associated with surgery or trauma, though bleeding phenotype can vary and is not 
always correlated to FXI coagulant activity. Deficiency is most common in Ashkenazi Jews (around 
1 in 190 are homozygous for mutation in the F11 gene and around 1 in 8 are heterozygous) but has 
TaBle 4 | Plasma pools used by the participants for FXi:ag assays.
Plasma pool number of laboratories
Local, fresh, and subsequently frozen 2
Local frozen 3
Lyophilized 1
Commercial frozen 5
TaBle 3 | antigen kits used by the participants for FXi:ag assays.
antibody kit/source number of laboratories
Cedarlane paired antibodies 2
Coachrom paired antibodies 2
Dunn Labortechnick kit 1
Molecular Innovation kit 1
VisuLize ELISA Kit, Affinity Biologicals 5
TaBle 2 | sources of deficient plasma used by the participants for FXi:c 
assays.
source of deficient plasma number of laboratories
Affinity Biologicals 3
American Diagnostica 1
Dade 1
Diagnostic Grifols 2
Diagnostica Stago 8
Hematologic Technologies 2
Helena Biosciences 1
Hyphen BioMed 1
Instrumentation Laboratory 5
Precision Biologic 2
Siemens 8
Technoclone 3
TaBle 1 | activated partial thromboplastin time (aPTT) reagents used by 
the participants for factor Xi (FXi):c assays.
aPTT reagent number of laboratories
Actin FS 5
Actin FSL 3
APTT-SP 5
Cephascreen 2
Cephen 1
CK Prest 4
Dapttin 1
DG-APTT Synth 1
Pathromtin SL 3
PTT A 1
Siron LS 1
SynthAFax 2
SynthASil 8
TaBle 5 | Overall geometric mean (gM) potencies, intra- and inter-
laboratory variation (expressed as gcV) for FXi:c and FXi:ag for the 
candidate niBsc code: 15/180 (samples a and B).
range of 
intra-laboratory 
variation (gcV)
inter-laboratory 
variation (gcV)
Overall gM in iU/amp  
(95% confidence limits)
FXI:C 0.54–13.0% 1.8% 0.71 (0.71–0.72)
FXI:Ag 1.1–13.0% 10.0% 0.78 (0.74–0.83)
TaBle 6 | Factor Xi (FXi):c, the geometric mean (gM) for each laboratory 
(iU/amp) for samples a and B (coded duplicates) combined and analyzed 
relative to sample s, the 1st is for FXi, plasma.
samples aB vs. sample s
lab gM (iU/amp) gcV (%)
1 0.68 3.40
2 0.73 1.40
3 0.71 4.00
4 0.71 2.10
5a 0.72 3.20
5b 0.71 2.30
5c 0.71 2.40
5d 0.71 2.20
8 0.73 1.70
9 0.70 2.10
10 0.71 4.00
11 0.70 0.54
12 0.72 1.90
13 0.71 2.30
14 0.72 4.40
16 0.71 1.60
17 0.78 4.70
18 0.72 1.60
19 0.71 1.80
20 0.70 4.30
21 0.71 2.90
22 0.72 2.70
23 0.72 2.30
24 0.72 2.30
25a 0.67 13.0
25b 0.72 1.60
26 0.74 –
27a 0.70 –
27b 0.72 13.00
27c 0.69 12.00
27d 0.71 3.30
28 0.71 2.60
29 0.70 0.96
30 0.71 1.10
31 0.70 2.30
Overall results for AB vs. S 0.71 (0.706–0.718) 2.30
Overall results for AB vs. S, excluding outliers 0.71 (0.706–0.715) 1.80
Intra-laboratory variation is shown as GCV (%). Lab 17 (shaded) was excluded from the 
overall analysis as an outlier. The overall GM and inter-laboratory GCV is also shown. 
Figures in brackets indicate the 95% confidence limits.
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now been identified in a wide variety of populations. There are a 
number of inherited mutations that cause FXI deficiency, most 
of which lead to a decrease in antigen and functional activity, 
though some patients (around 4%) experience a decrease in 
functional activity only (1).
The 1st International Standard (IS) for blood coagulation 
FXI, plasma (04/102), was established by the Expert Committee 
on Biological Standardization (ECBS) of the World Health 
Organization (WHO) in October 2005 (2). The standard is 
used to aid diagnosis of FXI deficiency and to assign potency 
to licensed FXI concentrates as well as control of virus inacti-
vated plasma products, both of which are used for treatment of 
FigUre 1 | histogram showing each laboratory’s geometric mean for FXi:c of samples a and B combined, relative to sample s, the 1st is for FXi, 
Plasma. Outliers are shown in red. The overall geometric mean was 0.71 IU/ampoule with a GCV of 1.8%.
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patients. As with most coagulation factors and inhibitors where 
the International Unit (IU) is defined as the amount of activity 
in 1 ml of pooled normal plasma, this first IS was assigned with 
FXI functional activity (FXI:C) relative to local normal plasma 
pools only. Due to the low stock level of this International 
Standard, a replacement standard is required. For traceability 
of the established IU for FXI:C, the replacement International 
Standard is value assigned relative to the preceding International 
Standard in a multicentre collaborative study. In addition, this 
study also aimed to establish an antigen value for FXI (FXI:Ag) 
for the same candidate. This would enable differentiation 
between patients who have low functional activity but normal 
antigen FXI levels and patients who have both low functional 
and antigen FXI levels.
MaTerials anD MeThODs
candidate WhO 2nd international 
standard for FXi, Plasma [national 
institute for Biological standards and 
control (niBsc) code 15/180]
Bulk material was purchased from the UK Blood Service in the 
form of plasma, which had been prepared by centrifugation of 
whole blood collected into CPD adenine anticoagulant. A sec-
ond centrifugation step was performed to remove all cellular 
material and the plasma rapidly frozen at −70°C. Individual 
donations were tested at source and found to be negative for 
HBsAg, anti-HIV-1 and HIV-2 antibodies, and anti-HCV. The 
material was prepared for filling by thawing immediately prior 
to use at 37°C and then pooled. Glycine and HEPES were added 
at a final concentration of 1% w/v and 40 mM, respectively. To 
avoid activation of FXI by cold activation or contact with glass, 
plastic vessels were used and the plasma was maintained at room 
temperature after thawing and throughout the duration of the 
fill. The preparation was filled into siliconized glass ampoules 
and freeze-dried over a 5-day cycle in accordance with recom-
mendations for the preparations of International Standards 
(3, 4). The 6,000 ampoules of 15/180 available have the following 
physical characteristics: mean fill mass of 1.0094 g (cv = 0.3%), 
mean dry weight of 0.0928 g (cv = 0.2%), mean residual mois-
ture of 0.605% (cv = 13.7%), and mean oxygen head space of 
0.23% (cv =  31.4%). The activation status of this preparation 
was investigated by the non-activated partial thromboplastin 
time, which is known to be sensitive to activated coagulation 
factors such as FXIa. The long mean clotting time of 300  s 
(n = 9; SD ± 2 s) for 15/180 indicates the sample to be relatively 
unactivated. Long-term stability of 15/180 has been assured by 
results from accelerated degradation study where activity of the 
preparations that have been stored at elevated temperature was 
compared with activity of the ampoules that have been stored 
at ultra-low temperature (−150°C). The predicted loss of FXI: 
C and FXI:Ag per year when the ampoules are stored at −20°C 
was 0.0025 and 0.039%, respectively.
samples in the study
The participants were provided with the 1st International 
Standard for FXI, Plasma (NIBSC code, 04/142), coded S and 
TaBle 7 | laboratory geometric means (gMs) for aB vs. s for activated partial thromboplastin time (aPTT reagents) actin Fs, synthasil, and aPTT-sP, 
their overall gM, and comparison to overall results for aB vs. s.
lab number (gM of aB vs. s, iU/amp) Overall gM, iU/amp  
(95% cl)
Overall gM of aB vs. s (all 
aPTT), iU/amp (95% cl)
Actin FS (n = 5) 1 (0.68) 3 (0.71) 5d (0.71) 29 (0.70) 30 (0.71) – – 0.70 (0.685–0.718) 0.71 (0.706–0.715)
SynthASil (n = 7) 2 (0.73) 10 (0.71) 11 (0.70) 20 (0.70) 22 (0.72) 23 (0.72) 31 (0.70) 0.71 (0.700–0.722)
APTT-SP (n = 5) 8 (0.73) 14 (0.72) 16 (0.71) 24 (0.72) 28 (0.71) – – 0.72 (0.707–0.728)
CL, confidence limits.
TaBle 8 | Factor Xi:c, the geometric mean (gM) for each laboratory for 
samples a and B (coded duplicates) combined and analyzed relative to 
sample P, each laboratory’s local plasma pool.
samples aB vs. sample P
lab gM (iU/amp) gcV (%)
1 0.68 9.10
2 0.66 6.70
3 0.70 4.20
4 0.79 7.60
5a 0.67 1.80
5b 0.72 2.50
5c 0.66 2.50
5d 0.65 2.10
8 0.75 3.60
9 0.75 10.00
10 0.66 4.30
11 0.78 5.00
12 0.74 1.60
13 0.67 6.10
14 0.80 2.20
16 0.80 5.70
17 0.71 1.80
18 0.84 5.40
19 0.74 3.10
20 0.76 4.70
21 0.71 4.70
22 0.70 0.91
23 0.70 3.60
24 0.68 3.20
25a 0.81 –
25b 0.83 3.60
26a 0.67 –
26b 0.72 3.80
27a 0.71 2.10
27b 0.75 –
27c 0.72 12.00
27d 0.71 3.60
28 0.66 3.90
29 0.71 4.70
30 0.68 5.30
31a 0.77 1.40
31b 0.74 1.90
Overall results for AB vs. P 0.72 (0.705–0.739) 7.20
Intra-laboratory variation is shown as GCV (%). The overall GM and inter-laboratory 
GCV for AB vs. P is also shown. Figures in brackets indicate the 95% confidence limits.
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the candidate material (NIBSC code, 15/180), as coded duplicate 
samples A and B. In addition, local plasma pools were required 
to assess the relationship between the IU and local plasma unit 
for FXI:C and to value assign the antigen (FXI:Ag) value. The 
participants were asked to collect fresh local plasma pools in 
the study for use both fresh, coded P1, and subsequently frozen, 
coded P2 during the study. NIBSC in-house studies on both FXI 
functional activity and FXI antigen have shown that there is no 
significant difference in results when using fresh plasma pools 
compared to the same pool of plasma used after freezing; there-
fore, if participants were unable to collect fresh plasma pools, 
then frozen plasma could be used as an alternative. Across the 
pools used in the study (fresh and frozen) for either functional 
activity or antigen value, plasma from more than 20,000 donors 
was used.
collaborative study
Of the 29 laboratories from 11 countries (Austria, Canada, Croatia, 
Denmark, France, Germany, Italy, The Netherlands, Spain, UK, 
USA) that took part in the FXI:C assignment, there were 8 clinical 
laboratories, 9 therapeutics producers, 6 diagnostics manufactur-
ers, 5 regulatory laboratories, and 1 research laboratory. Eleven 
laboratories (2 clinical laboratories, 1 diagnostics manufacturer, 
6 plasma therapeutics producers and 2 regulatory laboratories) 
from 8 countries (Austria, Canada, Denmark, France, Germany, 
Spain, UK, USA) carried out assays for FXI:Ag.
For FXI:C, participants were asked to assay coded duplicates 
A and B against sample S, the 1st IS for FXI Plasma. Since the FXI 
antigen is a new analyte, the unitage of the candidate standard 
was assigned relative to normal plasma pools. Participants were 
requested to perform their in-house methods for functional and 
antigen measurements. All assays for FXI:C were one-stage clot-
ting assays using activated partial thromboplastin time (APTT). 
In total, 13 different APTT reagents used across 14 different 
instrument platforms and a variety of deficient plasmas were 
employed by the participants and details of the reagents and 
deficient plasma used are indicated in Tables  1 and 2. For 
antigen assays, five different kits or paired antibody sets were 
used. The kits employed and the sources of local plasma pools 
used as the standard in the assays are listed in Tables 3 and 4, 
respectively.
For both FXI:C and FXI:Ag, four independent assays for 
each analyte were requested. A study protocol was provided, 
giving guidelines on randomization of samples and sufficient 
replication to enable statistical analysis. Raw data were returned 
to the NIBSC for parallel line analysis (5) with CombiStats 
software (CombiStats™, Version 5.0, Council of Europe). A log10 
transformation of the assay response was used for the analysis 
of the FXI antigen assays. No transformation was necessary for 
the FXI functional assays. All mean potencies were calculated as 
unweighted geometric mean (GM). Variability between assays 
and laboratories was expressed using geometric coefficients of 
5Wilmot et al. 2nd International Standard for FXI
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variation (GCV = {10s − 1} × 100% where s is the SD of the log10 
transformed potency estimates). Grubbs’ Test (6) was applied to 
the log-transformed laboratory mean estimates in order to detect 
any significant outliers. Comparisons between methods were 
made by appropriate t-tests of log-transformed laboratory mean 
estimates. One laboratory performed single point estimates only 
for FXI:C, hence was excluded from the overall analysis. Where 
a laboratory had performed more than one set of assays using a 
different APTT reagent or coagulometer, these data were treated 
independently.
resUlTs anD DiscUssiOn
FXi Functional assays
Analysis Relative to S, the 1st IS for FXI, Plasma
Results for samples A and B, the coded duplicates were analyzed 
relative to sample S, the 1st IS for FXI. The laboratories were able 
to perform precise assays; with intra-laboratory GCVs ranging 
from 0.54 to 13%, with the majority being less than 5% for both 
samples A or B (Table  5). The overall potency of A compared 
to S was 0.71 IU/amp, with a GCV of 1.60%. For B, it was also 
0.71  IU/amp, with a GCV of 2.40%. The good agreement of 
potencies for sample A and B, the coded duplicates, showed that 
there was no assay design bias and that the laboratories were 
able to measure FXI:C accurately. As there was no significant 
difference between the potency estimates for samples A and B 
(paired t-test, p =  0.218), potencies for samples A and B were 
combined to give the overall GM for the candidate preparation. 
FigUre 2 | histogram showing each laboratory’s geometric mean for FXi:c of samples a and B combined, relative to sample P, the laboratory’s 
local plasma pool. The overall geometric mean was 0.72 IU/ampoule with a GCV of 7.2%.
Each laboratory’s GM and intra-laboratory GCV are shown in 
Table 6. The overall result of AB vs. S was 0.71 IU/amp, the same 
as for A or B individually against S, and the inter-laboratory GCV 
was 1.80%. Results from Lab 17 were detected as statistical outli-
ers and were excluded from the overall calculation of potency 
and inter-laboratory GCV. The excellent agreement between the 
laboratories as shown by the close distribution of laboratory GMs 
is demonstrated in Figure 1.
Several of the laboratories used Actin FS, SynthASil, or 
APTT-SP as the APTT reagent in their assays. To determine if 
these reagents produced any method bias, the AB vs. S GMs of 
these laboratories were combined and compared to the overall 
GM. Table 7 shows that the results for Actin FS (0.70 IU/amp; 
5 laboratories), SynthASil (0.71  IU/amp; 7 laboratories), and 
APTT-SP (0.72 IU/amp; 5 laboratories) compared well with the 
overall GM of 0.71 IU/amp for AB, indicating no method bias. 
The overall GM of the other APTT reagents (excluding Actin FS, 
SynthASil, and APTT-SP) was 0.71 IU/amp, with 95% confidence 
limits of 0.70–0.72 IU/amp.
Analysis Relative to Plasma Pools (P)
Participants were asked to collect two plasma pools (P1 and 
P2) for use both as fresh and frozen pools in the assays. Where 
participants were unable to collect fresh plasma pools, it was 
requested that two different batches of local frozen plasma pools 
were used. In order to assess the relationship with the plasma 
unit (where the amount of FXI in 1 ml of plasma is taken to be 
1 U/ml), the data were analyzed relative to P. The overall GM for 
6Wilmot et al. 2nd International Standard for FXI
Frontiers in Medicine | www.frontiersin.org March 2017 | Volume 4 | Article 28
FigUre 3 |  histogram showing each laboratory’s individual assay results for FXi:ag of samples a and B combined, relative to sample P, the 
laboratory’s local plasma pool. The overall geometric mean was 0.78 U/ampoule with a GCV of 10.0%.  The inset shows each laboratory’s geometric mean for 
FXI:Ag samples A and B combined, relative to the laboratory’s local plasma pool (sample P).
sample A or B relative to P was 0.72 IU/amp, agreeing well with 
the potency of 0.71  IU/amp relative to S, the 1st International 
Standard for FXI, Plasma. The results for A and B relative to P 
were combined, and the overall results shown in Table  8 and 
Figure 2. The inter-laboratory variation was higher than for AB 
vs. S, at 7.20% overall, indicating the use of the International 
Standard improves inter-laboratory agreement. The overall GM 
for AB vs. P was 0.72 IU/amp, compared to 0.71 IU/amp relative 
to S. The results for AB vs. S and AB vs. P were compared using 
a paired two-tailed t-test and the result showed no significant 
difference between the two values (p =  0.215), indicating that 
a good relationship between the IU and the plasma unit had 
been maintained. A comparison of assays performed using fresh 
plasma pools to assays where frozen plasma pools were used 
showed there was no difference in the results between fresh and 
frozen pools (p = 0.704).
FXi antigen assays
Participants were asked to collect two plasma pools (P1 and 
P2) for use both as fresh and frozen pools in the assays. Where 
participants were unable to collect fresh plasma pools, it was 
requested that two different batches of local frozen plasma pools 
were used. As there is no current International Standard for FXI 
antigen, the units of FXI antigen in 1 ml of plasma pool was taken 
to be one, and the potencies of A and B calculated relative to 
the laboratories’ local plasma pool. Overall, the intra-laboratory 
variations ranged between 0.5 and 18%, with most laboratories 
having a GCV of less than 10% (Table 5). The variation of these 
assays would be expected to be higher than that of the FXI 
functional assays by virtue of the fact that the calculations are 
relative to the local plasma pools, which themselves have inher-
ent variability. Due to the low number of assays performed using 
fresh plasma pools (5), it was not possible to compare fresh and 
frozen plasma pools.
Since A and B were coded duplicates and paired t-test showed 
that there was no significant difference between the estimates for 
A and B (p = 0.198), the results were combined to give an overall 
TaBle 9 | Factor Xi:ag, the geometric mean (gM) for each laboratory for 
samples a and B (coded duplicates) combined and analyzed relative to 
sample P, each laboratory’s local plasma pool.
samples aB vs. sample P
lab gM (iU/amp) gcV (%)
6 0.70 11.00
7 0.94 5.80
14 0.81 4.50
15 0.79 9.70
16 0.86 13.00
17 0.71 2.80
18 0.89 13.00
20 0.80 9.40
24 0.71 3.80
26a 0.74 7.60
26b 0.76 11.00
28 0.72 1.10
Overall result for AB vs. P 0.78 (0.735–0.832) 10.00
Intra-laboratory variation is shown as GCV (%). The overall GM and inter-laboratory 
GCV for AB vs. P is also shown. Figures in brackets indicate the 95% confidence limits.
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result for AB against P. The overall GM was 0.78 IU/amp, with an 
acceptable inter-laboratory GCV of 10%. No statistical outliers 
were detected. The individual assay results from each lab and the 
laboratory GMs are shown in Table 9 and graphically in Figure 3.
Of the 12 laboratories that took part, 5 used an antigen kit 
from Affinity Biologicals. The GMs for AB against P of these 
laboratories were combined and resulted in a GM of 0.72 IU/amp 
(with 95% confidence limits of 0.70–0.75 IU/amp). This is slightly 
lower than the overall result for AB against P (0.78 IU/amp). The 
result for the other laboratories not using the Affinity Biologicals 
kit was 0.82 IU/amp, with 95% confidence limits of 0.75–0.90 IU/
amp, which overlap the overall GM of AB vs. P, but not that of the 
laboratories using the Affinity Biologicals kit. A comparison of 
the two groupings was made using the unpaired two-tailed t-test 
and the difference was found to be significant (p < 0.05). The dif-
ference suggests that the Affinity Biologicals kit may yield lower 
results than other kits; however, this could also be a reflection 
of the different plasma pools used within each laboratory. Due 
to the small number of laboratories taking part in the study and 
the fact that the two groupings had 95% confidence limits that 
were extremely close to being overlapping, the consensus GM 
was taken as the antigen value for the candidate preparation. Any 
effect of minor method bias on the results is likely to be small, 
especially for measurement around the normal range. For meas-
urements of abnormal samples, local qualification and validation 
of antigen method are advisable.
Based on the results of this study, the participants of the study 
and the Experts nominated by the Scientific and Standardization 
Committee (SSC) of the International Society on Thrombosis 
and Haemostasis (ISTH) agreed that the candidate preparation, 
NIBSC code: 15/180 is a suitable International Standard for 
FXI:C and FXI:Ag. In October 2016, the ECBS of the WHO 
established NIBSC code: 15/180 as the 2nd International Standard 
for FXI, plasma with assigned values of 0.71 and 0.78 IU/amp 
for FXI functional activity (FXI:C) and FXI antigen (FXI:Ag) 
respectively.
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